Kunihiro Nakai
Kunihiro Nakai has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aya Nakae
Presence Media Research Group, Hiroshi Ishiguro Laboratories, Deep Interaction Laboratory Group, Advanced Telecommunications Research Institute International (ATR), 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto 619-0288, Japan
2 shared publications Koichi Ueda
2 shared publicationsSosuke Oba
2 shared publicationsTakashi Mashimo
2 shared publications
Latest Publications
- 1 November 2010
- Published by Wiley in European journal of pain
- Vol. 14 (10) , 999-1006
5‐HT2C receptor agonists attenuate pain‐related behaviour in a rat model of trigeminal neuropathic pain
Peripheral branches of the trigeminal nerve may be damaged during maxillofacial injury or surgical procedures and trigeminal trauma may induce severe pain that is very challenging to treat. Chronic constriction injury to the infraorbital nerve (ION‐CCI) by loose ligatures has proven a useful model for some types of trigeminal neuropathic pain disorder. Using ION‐CCI rats, we examined the antiallodynic effects of intrathecally administered agents which are selective for 5‐HT2C receptors. Allodynia was evaluated by applying von Frey filaments to skin innervated by the injured ION. Dose‐dependent antiallodynic effects followed administration of three 5‐HT2C receptor agonists, 6‐chloro‐2‐(1‐piperazinyl)‐pyrazine (MK212: 10, 30, and 100 μg); (S)‐2‐(chloro‐5‐fluoro‐indol‐l‐yl)‐1‐methyamine fumarate (RO 60‐0175: 10, 30, and 100 μg); (AaR)‐8,9‐dichloro‐2,3,4,4a‐tetrahydro‐1H‐pyrazino[1,2‐a]quinoxalin‐5(6H)‐one (WAY‐161503: 10, 30, and 100 μg). ED50 values for antiallodynic effects of MK212, RO 60‐0175, and WAY‐161503 were 39.62, 46.67, and 51.22 μg, respectively. Intrathecal administration of the 5‐HT2C receptor antagonist, 8‐[5‐2,4‐dimethoxy‐5‐(4‐trifluoromethylphenylsulphonamido)phenyl‐5‐oxopentyl]‐1,3,8‐triazaspiro[4,5]decane‐2,4‐dione (RS‐102221: 30 μg) did not alter the mechanical threshold. Intrathecal pretreatment with RS‐102221 (10 and 30 μg) reduced the antiallodynic effects of the highest dose of 5‐HT2C agonists. These results indicated that, in this rat model, the 5‐HT2C receptor plays a role in spinal inhibition of trigeminal neuropathic pain.
- 1 November 2010
- Published by Wiley in European journal of pain
- Vol. 14 (10) , 999-1006
5‐HT2C receptor agonists attenuate pain‐related behaviour in a rat model of trigeminal neuropathic pain
Peripheral branches of the trigeminal nerve may be damaged during maxillofacial injury or surgical procedures and trigeminal trauma may induce severe pain that is very challenging to treat. Chronic constriction injury to the infraorbital nerve (ION‐CCI) by loose ligatures has proven a useful model for some types of trigeminal neuropathic pain disorder. Using ION‐CCI rats, we examined the antiallodynic effects of intrathecally administered agents which are selective for 5‐HT2C receptors. Allodynia was evaluated by applying von Frey filaments to skin innervated by the injured ION. Dose‐dependent antiallodynic effects followed administration of three 5‐HT2C receptor agonists, 6‐chloro‐2‐(1‐piperazinyl)‐pyrazine (MK212: 10, 30, and 100 μg); (S)‐2‐(chloro‐5‐fluoro‐indol‐l‐yl)‐1‐methyamine fumarate (RO 60‐0175: 10, 30, and 100 μg); (AaR)‐8,9‐dichloro‐2,3,4,4a‐tetrahydro‐1H‐pyrazino[1,2‐a]quinoxalin‐5(6H)‐one (WAY‐161503: 10, 30, and 100 μg). ED50 values for antiallodynic effects of MK212, RO 60‐0175, and WAY‐161503 were 39.62, 46.67, and 51.22 μg, respectively. Intrathecal administration of the 5‐HT2C receptor antagonist, 8‐[5‐2,4‐dimethoxy‐5‐(4‐trifluoromethylphenylsulphonamido)phenyl‐5‐oxopentyl]‐1,3,8‐triazaspiro[4,5]decane‐2,4‐dione (RS‐102221: 30 μg) did not alter the mechanical threshold. Intrathecal pretreatment with RS‐102221 (10 and 30 μg) reduced the antiallodynic effects of the highest dose of 5‐HT2C agonists. These results indicated that, in this rat model, the 5‐HT2C receptor plays a role in spinal inhibition of trigeminal neuropathic pain.
- 2 June 2010
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 21 (8) , 559-563
P2X4 receptor expression in a rat model of trigeminal neuropathic pain
We investigated the P2X4 receptor (P2X4R) expression in the cervical spinal cord, trigeminal ganglion, and infraorbital nerve (ION), after a chronic constriction injury of unilateral ION and a treatment with selective serotonin reuptake inhibitor (SSRI). A recent study has showed that SSRI inhibits P2X4R expression. Injured rats had significantly lower pain thresholds. In injured and slightly injured ION, the P2X4R expression was significantly higher than in the naïve-rat ION. Injured animals with SSRI showed significantly higher pain thresholds than injured animals without the drug. Nonetheless, P2X4R expression in the ipsilateral ION remained high. Immunostaining showed that macrophages are the source of P2X4R. Our results suggest that the expression of P2X4R in our model is modulated not by neuropathic pain, but by slight nerve injury.
- 2 June 2010
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 21 (8) , 559-563
P2X4 receptor expression in a rat model of trigeminal neuropathic pain
We investigated the P2X4 receptor (P2X4R) expression in the cervical spinal cord, trigeminal ganglion, and infraorbital nerve (ION), after a chronic constriction injury of unilateral ION and a treatment with selective serotonin reuptake inhibitor (SSRI). A recent study has showed that SSRI inhibits P2X4R expression. Injured rats had significantly lower pain thresholds. In injured and slightly injured ION, the P2X4R expression was significantly higher than in the naïve-rat ION. Injured animals with SSRI showed significantly higher pain thresholds than injured animals without the drug. Nonetheless, P2X4R expression in the ipsilateral ION remained high. Immunostaining showed that macrophages are the source of P2X4R. Our results suggest that the expression of P2X4R in our model is modulated not by neuropathic pain, but by slight nerve injury.